Skip to main content
main-content

Pioglitazone

News

09-17-2018 | Prediabetes | medwireNews | News

Targeting pathophysiology from outset may slow progression to type 2 diabetes

Upfront treatment with medications that target the underlying pathophysiology of prediabetes may slow patients’ progression to type 2 diabetes, report researchers.

10-24-2017 | Pioglitazone | News

Patients treated with pioglitazone may have reduced gout risk

Observational findings suggest that pioglitazone use may be associated with a reduced risk for gout among patients with diabetes.

09-13-2017 | Pioglitazone | EASD 2017 | News

TOSCA.IT: Similar long-term CV safety profile for pioglitazone, sulfonylurea

 The TOCSA.IT investigators have found no differences in cardiovascular disease outcomes between patients with type 2 diabetes taking pioglitazone versus sulfonylurea over nearly 5 years.

Read more

Related topics

Superior

Related

Journal articles and book chapters

06-09-2018 | Cardiovascular disorders | Review | Article

Molecular mechanisms underlying the cardiovascular benefits of SGLT2i and GLP-1RA

Khat DZ, Husain M. Curr Diab Rep 2018; 18: 45. doi: 10.1007/s11892-018-1011-7

06-08-2018 | Insulin resistance | Review | Article

Chronic kidney disease-induced insulin resistance: Current state of the field

Dave N, Wu J, Thomas S. Curr Diab Rep 2018; 18: 44. doi: 10.1007/s11892-018-1010-8

05-18-2018 | Gestational diabetes | Review | Article

Not quite type 1 or type 2, what now? Review of monogenic, mitochondrial, and syndromic diabetes

Yeung RO et al. Rev Endocr Metab Disord 2018. doi: 10.1007/s11154-018-9446-3